#USA #Dublin #Jazz Pharmaceuticals #Epidiolex #Xywav

Jazz Pharmaceuticals Financial Recap and 2026 Guidance

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has recently unveiled its financial results for the full year and the fourth quarter of 2025, showcasing impressive growth and a bright outlook for 2026.

Financial Highlights of 2025

In 2025, Jazz Pharmaceuticals achieved total revenues of $4.3 billion, marking a 5% increase from the previous year. The fourth quarter was particularly noteworthy, with revenues reaching $1.2 billion, representing a year-over-year growth of 10% and positioning it as the company's highest quarterly revenue to date.

Renee Gala, President and CEO of Jazz, expressed pride in the company’s operational excellence, emphasizing how the results reflect their commitment to innovation for patients. Notable product achievements included:

• - Xywav®: Recorded revenues of $1.7 billion and a 12% year-over-year growth.
• - Epidiolex®: This product generated $1.1 billion in revenue, growing by 9% compared to the previous year.
• - The recent launch of Modeyso™ yielded $37 million in its first free quarter on the market.

2026 Financial Guidance

Looking ahead, Jazz Pharmaceuticals anticipates total revenue between $4.25 billion and $4.50 billion in 2026, continuing its trajectory of double-digit growth, especially in its epilepsy and oncology franchises. These figures are backed by strong commercial momentum and a pipeline filled with promising therapies.

Key Developments in Research and Development

Jazz's pipeline saw significant advancements in 2025, particularly with the HERIZON-GEA-01 trial results for zanidatamab, a potential game-changer for HER2-positive metastatic gastroesophageal adenocarcinoma (GEA). The company forecasts that submissions for zanidatamab will be completed in the first quarter of 2026, with the potential launch in late 2026. Additionally, plans are in place for multiple clinical trials targeting various indications, including metastatic breast cancer.

Rob Iannone, M.D., M.S.C.E., Chief Medical Officer, highlighted how these advancements not only position zanidatamab as a leading treatment option but also underscore Jazz's commitment to addressing unmet patient needs.

Commercial Performance and Market Leadership

Jazz Pharmaceuticals continues to solidify its standing in the rare sleep disorder market, with Xywav leading the charge. The total sleep franchise achieved over $2 billion in revenues for the year. The company's significant investments in R&D have laid a foundation for sustained growth and expansion into territories with high unmet needs.

In addition, the company has made strategic acquisitions, such as Chimerix Inc., which has complemented its product offering and research capabilities. The recently acquired Modeyso, developed for treating a specific type of glioma, showcases Jazz's dedication to rare disease therapies.

Summary

Overall, Jazz Pharmaceuticals' robust financial performance in 2025 and promising outlook for 2026 indicate a sustained commitment to patient-oriented innovation and strategic growth within its therapeutic areas. The company’s leadership remains optimistic that it will continue to create lasting value for both patients and shareholders as it advances its mission to transform lives through innovative medicines.